Hormonal
Ghrelin is an endogenous peptide hormone that stimulates food intake and growth hormone secretion, with its circulating levels inversely correlated with energy balance (increasing during fasting/starvation and decreasing during feeding/obesity).
Understand that hunger is biologically regulated by ghrelin, which rises when you are fasting or have low energy stores and falls after eating. In obesity, this system is often blunted, with lower baseline ghrelin levels, which may contribute to the difficulty in regulating food intake. Recognizing this hormonal drive can help separate biological hunger from emotional or habitual eating.
Ghrelin, identified as an endogenous ligand for the growth hormone secretagogue receptor, functions as a somatotrophic and orexigenic signal from the stomach... The secretion of ghrelin increases under conditions of negative energy-balance, such as starvation, cachexia, and anorexia nervosa, whereas its expression decreases under conditions of positive energy-balance such as feeding, hyperglycemia, and obesity.
Why this rating
This is a comprehensive review by the discoverers of ghrelin, citing numerous primary studies, but it summarizes existing data rather than presenting new primary clinical trial data.
Source
Biological, Physiological, and Pharmacological Aspects of Ghrelin
Hiroshi Hosoda et al. · Journal of Pharmacological Sciences · 2006
DOI 10.1254/jphs.crj06002x
More from this paper
- Ghrelin stimulates food intake and growth hormone release primarily through the vagus nerve and hypothalamic pathways (NPY/AgRP neurons), rather than solely by crossing the blood-brain barrier.Good
- Gastric bypass surgery reduces circulating ghrelin levels significantly, which may contribute to weight loss by suppressing appetite, although the mechanism is not fully understood.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →